Chimerix (CMRX) Akcie Kurz
Chimerix Kurz
Tržby Chimerix klesaly o 13,9 % ročně za posledních 14 let na 212 000,00 USD. U Chimerix je čistá marže -41 692,0 % dolů oproti -784,2 % před několika lety. Konsenzuální 12měsíční cílová cena pro Chimerix je 8,72 USD, asi nad cenu o 2,1 %. Z 11 analytiků jich 10 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Chimerix
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Chimerix a analýza akcií
Nejčastější otázky týkající se akcie Chimerix
Chimerix Inc. operates with a business model focused on the development and commercialization of innovative antiviral therapeutics. The company aims to address unmet medical needs and improve patients' lives through the discovery, research, and development of novel antiviral medications. Chimerix Inc. primarily focuses on developing oral nucleotide analogs that target viral replication and replication pathways, aiming to provide effective treatments for various viral infections. With its commitment to advancing medical science, Chimerix Inc. leverages its expertise to create valuable pharmaceutical solutions, contributing to the advancement of antiviral therapeutics.
Chimerix Inc primarily operates in the biotechnology and pharmaceutical industries.
The main competitors of Chimerix Inc in the market include pharmaceutical companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline.
Chimerix Inc is a pharmaceutical company based in Durham, North Carolina. Founded in 2002, the company primarily focuses on the development and commercialization of innovative antiviral therapeutics. Chimerix has a rich history in the field of antiviral research and has made significant contributions to the medical community. The company's mission is to discover, develop, and deliver novel medicines to improve the lives of patients suffering from life-threatening diseases. With a dedicated team of scientists and researchers, Chimerix continues to advance its pipeline of antiviral drugs, providing hope for patients worldwide.
Chimerix Inc has achieved significant milestones throughout its history. One notable achievement was the successful completion of Phase 3 clinical trials for its antiviral drug, brincidofovir. This marked a crucial milestone in the company's efforts to develop an effective treatment for viral infections, including cytomegalovirus. Additionally, Chimerix Inc has secured multiple partnerships and collaborations with renowned healthcare organizations and research institutions. These partnerships have paved the way for further advancements in Chimerix's drug development pipeline and enhanced its potential to address unmet medical needs. Chimerix Inc continues to strive for further milestones and innovations in the field of antiviral therapeutics.
Chimerix Inc is primarily present in the United States.
Chimerix Inc is a biopharmaceutical company that is committed to improving the lives of patients suffering from life-threatening diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centered care. Chimerix Inc values scientific excellence, integrity, and transparency in all aspects of their operations. They strive to develop novel antiviral therapies to address unmet medical needs. With a dedicated team of experts, Chimerix Inc focuses on delivering innovative solutions that can make a significant impact in the medical field. This commitment to patients, scientific advancement, and ethical practices defines Chimerix Inc and sets them apart in the biopharmaceutical industry.
Analytici aktuálně stanovují průměrnou cílovou cenu 8,71 USD pro akcii Chimerix (medián: 8,72 USD), tedy +2,0 % vůči poslední ceně. Konsensus vychází z 11 hodnocení analytiků.
11 analytiků aktuálně hodnotí akcii Chimerix: 7 doporučuje koupit, 4 držet a 0 prodat. Pro rok 2026 analytici očekávají u Chimerix tržby 38,60 Mil. USD a zisk na akcii -0,81 USD.
Při aktuálním kurzu se akcie Chimerix obchoduje za 7,65 EUR (8,54 USD).
Akcie Chimerix (CMRX) je kótována na 5 burzách, mimo jiné: NASDAQ (CMRX), SIX (Zürich) (CXF.SW), Frankfurt (CXF.F), München (CXF.MU), Düsseldorf (CXF.DU).
Chimerix Inc is a US biotech company specializing in the development of antiviral and immunoncology therapeutics. It was founded in 2000 and is headquartered in Durham, North Carolina. The company's business model focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases and cancer. Chimerix operates in two main areas: infectious diseases and cancer. In infectious diseases, its leading product is Brincidofovir (BCV) for the treatment of life-threatening virus infections such as cytomegalovirus (CMV) and adenovirus infections. In cancer therapy, Chimerix has multiple products in its pipeline that aim to activate the immune system to fight tumors. The company collaborates with leading academic and clinical research institutions and utilizes various business models to market its products, including partnerships with government-funded research programs and multinational pharmaceutical companies. Overall, Chimerix has a promising pipeline of products in clinical studies and is well-positioned to improve global patient care.
Tržby očekávané za Chimerix činí 38,60 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Chimerix činí -73,55 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Chimerix je aktuálně -10,48. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Chimerix.
Poměr ceny k tržbám (P/S) Chimerix je aktuálně 19,97. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Chimerix.
Score kvality pro Chimerix je 2/10.
ISIN Chimerix je US16934W1062. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Chimerix je A1T65B. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Chimerix je CMRX. Symbol tickeru se používá k obchodování akcií Chimerix na burze.
Chimerix akcie
Chimerix Peer Group
Chimerix Ticker
Chimerix FIGI
Všechny fundamentální údaje o Chimerix v podrobné analýze
Naše analýzy akcií společnosti Chimerix zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Chimerix. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: